Catabasis (CATB) Partners With UK-Based Charity For DMD Study
Zacks Investment Research | Jan 09, 2020 04:09AM ET
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced that it has entered into a partnership with Duchenne UK, a charity to fund its phase II study on the lead pipeline candidate edasalonexent, an NF-kB inhibitor for the treatment of non-ambulatory Duchenne muscular dystrophy (DMD).
Duchenne UK is a London-based charity that provides funds to accelerate treatments for DMD.
The aforementioned exploratory study, subject to the receipt of adequate funding, will assess the safety, pharmacokinetics and exploratory measures of function including cardiac, skeletal muscle and pulmonary function in the given patient population.
The study will enroll approximately 16 non-ambulatory patients aged 10 years and above regardless of mutation type and who have been off steroids for minimum six months in the United Kingdom. Upon completion, patients will have the option to move to Catabasis’ new open-label extension study GalaxyDMD to receive edasalonexent.
Catabasis initiated GalaxyDMD, which is designed to provide longer-term safety data for supporting registration filings in March 2019.
Shares of Catabasis have increased 7.8% in the past year against the industry’s decrease of 4.2%.
Notably, edasalonexent is also being developed in an ongoing phase III PolarisDMD study for the treatment of DMD regardless of mutation type. It will evaluate the efficacy and safety of edasalonexent for registration purposes. Top-line data from the same is expected in the fourth quarter of 2020.
Edasalonexent is also being developed for other forms of muscular dystrophy, such as becker muscular dystrophy (BMD).
Meanwhile, in August 2019, Catabasis entered into a preclinical research collaboration to study edasalonexent for Dysferlinopathy with the Jain Foundation, a non-profit foundation with an aim to cure muscular dystrophies caused by dysferlin protein deficiency.
Zacks Rank & Stocks to Consider
Catabasis currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include PDL BioPharma, Inc. (NASDAQ:PDLI) , Emergent Biosolutions Inc. (NYSE:EBS) and ObsEva SA (NASDAQ:OBSV) , all sporting a Zacks Rank #1 (Strong Buy). You can see .
PDL BioPharma’s earnings estimates have been revised 22.2% upward for 2020 over the past 60 days.
Emergent’s earnings estimates have moved 5.6% north for 2020 over the past 60 days.
Get The News You Want
ObsEva’s loss per share estimates have narrowed 4.3% for 2020 over the past 60 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0% and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.